CLINICAL TRIALS PROFILE FOR ARBACLOFEN PLACARBIL

Clinical Trials for Arbaclofen Placarbil

Trial ID	Title	Status	Sponsor	Phase	Summary
NCT00557401 ↗	An Efficacy and Safety Study of XP19986 in Subjects With Symptomatic GERD	Completed	Indivior Inc.	Phase 2	To evaluate efficacy and safety of treatment with XP19986 Sustained Release (SR) Tablet compared to placebo in subjects with symptomatic GERD
NCT00557401 ↗	An Efficacy and Safety Study of XP19986 in Subjects With Symptomatic GERD	Completed	XenoPort, Inc.	Phase 2	To evaluate efficacy and safety of treatment with XP19986 Sustained Release (SR) Tablet compared to placebo in subjects with symptomatic GERD
NCT00817986 ↗	A Study to Evaluate the Safety and Tolerability of Arbaclofen Placarbil (XP19986) in Subjects With Acute Back Spasms	Completed	Indivior Inc.	Phase 2	The purpose of the study is to evaluate safety and tolerability of arbaclofen placarbil sustained release tablets taken every 12 hours compared to placebo in subjects with acute back spasms in the lumbar region.
NCT00817986 ↗	A Study to Evaluate the Safety and Tolerability of Arbaclofen Placarbil (XP19986) in Subjects With Acute Back Spasms	Completed	XenoPort, Inc.	Phase 2	The purpose of the study is to evaluate safety and tolerability of arbaclofen placarbil sustained release tablets taken every 12 hours compared to placebo in subjects with acute back spasms in the lumbar region.
NCT00978016 ↗	A Study to Evaluate the Efficacy and Safety of Arbaclofen Placarbil (XP19986) as Adjunctive Therapy in Subjects With Gastroesophageal Reflux Disease (GERD)	Completed	Indivior Inc.	Phase 2	The purpose of the study is to evaluate efficacy and safety of arbaclofen placarbil (XP19986) versus placebo as adjunctive therapy in subjects with troublesome GERD symptoms despite therapy with approved doses of a Proton Pump Inhibitor (PPI).
NCT00978016 ↗	A Study to Evaluate the Efficacy and Safety of Arbaclofen Placarbil (XP19986) as Adjunctive Therapy in Subjects With Gastroesophageal Reflux Disease (GERD)	Completed	XenoPort, Inc.	Phase 2	The purpose of the study is to evaluate efficacy and safety of arbaclofen placarbil (XP19986) versus placebo as adjunctive therapy in subjects with troublesome GERD symptoms despite therapy with approved doses of a Proton Pump Inhibitor (PPI).

Clinical Trial Conditions for Arbaclofen Placarbil

Condition Name

Condition Name for
Intervention	Trials
Alcohol Use Disorder	1
Back Pain	1
Gastroesophageal Reflux	1
Gastroesophageal Reflux Disease	1

Condition MeSH

Condition MeSH for
Intervention	Trials
Gastroesophageal Reflux	2
Esophagitis, Peptic	1
Back Pain	1
Disease	1

Clinical Trial Locations for Arbaclofen Placarbil

Trials by Country

Trials by Country for
Location	Trials
United States	59
Canada	1
United Kingdom	1

Trials by US State

Trials by US State for
Location	Trials
California	4
Florida	4
Texas	3
North Carolina	3
New Jersey	3

Clinical Trial Progress for Arbaclofen Placarbil

Clinical Trial Phase

Clinical Trial Phase for
Clinical Trial Phase	Trials
Phase 3	1
Phase 2	4
Phase 1	1

Clinical Trial Status

Clinical Trial Status for
Clinical Trial Phase	Trials
Completed	6

Clinical Trial Sponsors for Arbaclofen Placarbil

Sponsor Name

Sponsor Name for
Sponsor	Trials
Indivior Inc.	6
XenoPort, Inc.	4

Sponsor Type

Sponsor Type for
Sponsor	Trials
Industry	10